File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

TitleHPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
Authors
Joura, EAKjaer, SKWheeler, CMSigurdsson, KIversen, OEHernandezAvila, MPerez, GBrown, DRKoutsky, LATay, EHGarcía, PAult, KAGarland, SMLeodolter, SOlsson, SETang, GWKFerris, DGPaavonen, JLehtinen, MSteben, MBosch, XDillner, JKurman, RJMajewski, SMuñoz, NMyers, ERVilla, LLTaddeo, FJRoberts, CTadesse, ABryan, JLupinacci, LCGiacoletti, KEDLu, SVuocolo, SHesley, TMHaupt, RMBarr, E
KeywordsHuman Papillomavirus
Humoral immunity
Immune memory
Issue Date2008
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2008, v. 26 n. 52, p. 6844-6851 How to Cite?
DOI: http://dx.doi.org/10.1016/j.vaccine.2008.09.073
AbstractThe efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers. © 2008 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/173340
ISSN
0264-410X
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.342
ISI Accession Number ID
WOS:000261898400019
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorJoura, EAen_US
dc.contributor.authorKjaer, SKen_US
dc.contributor.authorWheeler, CMen_US
dc.contributor.authorSigurdsson, Ken_US
dc.contributor.authorIversen, OEen_US
dc.contributor.authorHernandezAvila, Men_US
dc.contributor.authorPerez, Gen_US
dc.contributor.authorBrown, DRen_US
dc.contributor.authorKoutsky, LAen_US
dc.contributor.authorTay, EHen_US
dc.contributor.authorGarcía, Pen_US
dc.contributor.authorAult, KAen_US
dc.contributor.authorGarland, SMen_US
dc.contributor.authorLeodolter, Sen_US
dc.contributor.authorOlsson, SEen_US
dc.contributor.authorTang, GWKen_US
dc.contributor.authorFerris, DGen_US
dc.contributor.authorPaavonen, Jen_US
dc.contributor.authorLehtinen, Men_US
dc.contributor.authorSteben, Men_US
dc.contributor.authorBosch, Xen_US
dc.contributor.authorDillner, Jen_US
dc.contributor.authorKurman, RJen_US
dc.contributor.authorMajewski, Sen_US
dc.contributor.authorMuñoz, Nen_US
dc.contributor.authorMyers, ERen_US
dc.contributor.authorVilla, LLen_US
dc.contributor.authorTaddeo, FJen_US
dc.contributor.authorRoberts, Cen_US
dc.contributor.authorTadesse, Aen_US
dc.contributor.authorBryan, Jen_US
dc.contributor.authorLupinacci, LCen_US
dc.contributor.authorGiacoletti, KEDen_US
dc.contributor.authorLu, Sen_US
dc.contributor.authorVuocolo, Sen_US
dc.contributor.authorHesley, TMen_US
dc.contributor.authorHaupt, RMen_US
dc.contributor.authorBarr, Een_US
dc.date.accessioned2012-10-30T06:29:29Z-
dc.date.available2012-10-30T06:29:29Z-
dc.date.issued2008en_US
dc.identifier.citationVaccine, 2008, v. 26 n. 52, p. 6844-6851en_US
dc.identifier.issn0264-410Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/173340-
dc.description.abstractThe efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers. © 2008 Elsevier Ltd. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_US
dc.relation.ispartofVaccineen_US
dc.rightsVaccine. Copyright © Elsevier Ltd.-
dc.subjectHuman Papillomavirus-
dc.subjectHumoral immunity-
dc.subjectImmune memory-
dc.subject.meshAdolescenten_US
dc.subject.meshAntibodies, Viral - Analysis - Biosynthesis - Immunologyen_US
dc.subject.meshCondylomata Acuminata - Epidemiology - Immunology - Prevention & Controlen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHuman Papillomavirus 11 - Immunologyen_US
dc.subject.meshHuman Papillomavirus 16 - Immunologyen_US
dc.subject.meshHuman Papillomavirus 18 - Immunologyen_US
dc.subject.meshHuman Papillomavirus 6 - Immunologyen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunization Scheduleen_US
dc.subject.meshPapillomavirus Infections - Immunology - Pathology - Prevention & Controlen_US
dc.subject.meshPapillomavirus Vaccines - Immunologyen_US
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen_US
dc.subject.meshVagina - Pathologyen_US
dc.subject.meshVaginal Smearsen_US
dc.subject.meshVulva - Pathologyen_US
dc.subject.meshYoung Adulten_US
dc.titleHPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccineen_US
dc.typeArticleen_US
dc.identifier.emailTang, GWK:gwktang@hkucc.hku.hken_US
dc.identifier.authorityTang, GWK=rp00328en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.vaccine.2008.09.073en_US
dc.identifier.pmid18930097-
dc.identifier.scopuseid_2-s2.0-56949087305en_US
dc.identifier.hkuros166995-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-56949087305&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume26en_US
dc.identifier.issue52en_US
dc.identifier.spage6844en_US
dc.identifier.epage6851en_US
dc.identifier.isiWOS:000261898400019-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridJoura, EA=7004817276en_US
dc.identifier.scopusauthoridKjaer, SK=7004418213en_US
dc.identifier.scopusauthoridWheeler, CM=7202505711en_US
dc.identifier.scopusauthoridSigurdsson, K=35475355400en_US
dc.identifier.scopusauthoridIversen, OE=7102966661en_US
dc.identifier.scopusauthoridHernandezAvila, M=7005968193en_US
dc.identifier.scopusauthoridPerez, G=16307983600en_US
dc.identifier.scopusauthoridBrown, DR=7407095050en_US
dc.identifier.scopusauthoridKoutsky, LA=7006120337en_US
dc.identifier.scopusauthoridTay, EH=7004902850en_US
dc.identifier.scopusauthoridGarcía, P=7201693727en_US
dc.identifier.scopusauthoridAult, KA=7005241226en_US
dc.identifier.scopusauthoridGarland, SM=7102220459en_US
dc.identifier.scopusauthoridLeodolter, S=7005056838en_US
dc.identifier.scopusauthoridOlsson, SE=7202623557en_US
dc.identifier.scopusauthoridTang, GWK=7401633864en_US
dc.identifier.scopusauthoridFerris, DG=17634377600en_US
dc.identifier.scopusauthoridPaavonen, J=7102724434en_US
dc.identifier.scopusauthoridLehtinen, M=35479268300en_US
dc.identifier.scopusauthoridSteben, M=6602790643en_US
dc.identifier.scopusauthoridBosch, X=23990295900en_US
dc.identifier.scopusauthoridDillner, J=7007135194en_US
dc.identifier.scopusauthoridKurman, RJ=7101640655en_US
dc.identifier.scopusauthoridMajewski, S=7103224726en_US
dc.identifier.scopusauthoridMuñoz, N=7102360543en_US
dc.identifier.scopusauthoridMyers, ER=35433205900en_US
dc.identifier.scopusauthoridVilla, LL=7102824355en_US
dc.identifier.scopusauthoridTaddeo, FJ=6603004214en_US
dc.identifier.scopusauthoridRoberts, C=35474924800en_US
dc.identifier.scopusauthoridTadesse, A=6602812727en_US
dc.identifier.scopusauthoridBryan, J=7202481712en_US
dc.identifier.scopusauthoridLupinacci, LC=16307166200en_US
dc.identifier.scopusauthoridGiacoletti, KED=15131768700en_US
dc.identifier.scopusauthoridLu, S=54899768500en_US
dc.identifier.scopusauthoridVuocolo, S=16403558200en_US
dc.identifier.scopusauthoridHesley, TM=6603486789en_US
dc.identifier.scopusauthoridHaupt, RM=11940557600en_US
dc.identifier.scopusauthoridBarr, E=7005643832en_US
dc.identifier.citeulike3445864-
dc.identifier.issnl0264-410X-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats